MEDREICH PARACETAMOL PLUS CODEINE 500/9.6 paracetamol 500 mg and codeine phosphate hemihydrate 9.6 mg tablet blister pack Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

medreich paracetamol plus codeine 500/9.6 paracetamol 500 mg and codeine phosphate hemihydrate 9.6 mg tablet blister pack

medreich australia pty ltd - codeine phosphate hemihydrate, quantity: 9.6 mg; paracetamol, quantity: 499.9995 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; quinoline yellow aluminium lake; povidone; croscarmellose sodium; pregelatinised maize starch; maize starch; stearic acid; crospovidone - for the temporary relief of acute moderate pain in patients over the age of 12 years.

TRUST IBUPROFEN PLUS CODEINE film coated tablet blister pack Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

trust ibuprofen plus codeine film coated tablet blister pack

pharmacor pty ltd - codeine phosphate hemihydrate, quantity: 12.8 mg; ibuprofen, quantity: 200 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - for temporary relief of acute moderate pain and inflammation in patients over the age of 12 years

Boots Ibuprofen and Codeine 200mg / 12.8 mg film-coated tablets Írsko - angličtina - HPRA (Health Products Regulatory Authority)

boots ibuprofen and codeine 200mg / 12.8 mg film-coated tablets

the boots company plc - ibuprofen; codeine phosphate hemihydrate - film-coated tablet - 200 mg/12.8 milligram(s) - opioids in combination with non-opioid analgesics; codeine and ibuprofen

Paracetamol/Codeine 500 mg/30 mg, effervescent tablets Írsko - angličtina - HPRA (Health Products Regulatory Authority)

paracetamol/codeine 500 mg/30 mg, effervescent tablets

bristol laboratories limited - codeine phosphate hemihydrate; paracetamol - effervescent tablet - 500/30 milligram(s) - opioids in combination with non-opioid analgesics; codeine and paracetamol

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE syrup Spojené štáty - angličtina - NLM (National Library of Medicine)

promethazine hydrochloride and codeine phosphate syrup

apotheca inc - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - codeine phosphate 10 mg in 5 ml - promethazine hydrochloride and codeine phosphate syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. the combination of promethazine hydrochloride and codeine phosphate is contraindicated in pediatric patients less than 6 years of age, because the combination may cause fatal respiratory depression in this age population. codeine sulfate is contraindicated for postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy. codeine is contraindicated in patients with a known hypersensitivity to the drug. promethazine is contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines and codeine are both contraindicated for use in the treatment of lower respiratory tract symptoms, including asthma. promethazine hydrochloride and codeine phosphate syrup is a schedule v controlled substance

BUTALBITAL, ACETAMINOPHEN, CAFFEINE, AND CODEINE PHOSPHATE- codeine phosphate, butalbital, caffeine, and acetaminophen capsule c Spojené štáty - angličtina - NLM (National Library of Medicine)

butalbital, acetaminophen, caffeine, and codeine phosphate- codeine phosphate, butalbital, caffeine, and acetaminophen capsule c

physicians total care, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine - unii:q830pw7520), butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - codeine phosphate 30 mg - butalbital, acetaminophen, caffeine, and codeine phosphate capsules is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of butalbital, acetaminophen, caffeine, and codeine phosphate capsules in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because codeine and butalbital are habit-forming and potentially abusable. butalbital, acetaminophen, caffeine, and codeine phosphate capsules is contraindicated under the following conditions: −  hypersensitivity or intolerance to acetaminophen, caffeine, butalbital, or codeine. −  patients with porphyria. butalbital, acetaminophen, caffeine, and codeine phosphate capsules is controlled by the drug enforcement administration and is classified under schedule iii. codeine codeine can produce drug dependence of the morphine type and, therefore, has the potential for being abused. psychological dependence, physical dependence,

FIORINAL WITH CODEINE- butalbital, aspirin, caffeine, and codeine phosphate capsule Spojené štáty - angličtina - NLM (National Library of Medicine)

fiorinal with codeine- butalbital, aspirin, caffeine, and codeine phosphate capsule

actavis pharma, inc. - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - codeine phosphate 30 mg - fiorinal with codeine is indicated for the management of the symptom complex of tension (or muscle contraction) headache, when non-opioid analgesic and alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse with opioids and butalbital, even at recommended doses [see warnings and precautions ( 5.1 )] , reserve fiorinal with codeine for use in patients for whom alternative treatment options (e.g., non-opioid, non-barbiturate analgesics): •       have not been tolerated, or are not expected to be tolerated, •       have not provided adequate analgesia, or are not expected to provide adequate analgesia fiorinal with codeine is contraindicated for : • all children younger than 12 years of age [see warnings and precautions (5.4)] • postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see warnings and precautions (5.4)] . fiorinal with codeine is also contraindicated in patients with: • significant r

PROMETHAZINE VC WITH CODEINE- promethazine and phenylephrine hydrochloride and codeine phosphate solution Spojené štáty - angličtina - NLM (National Library of Medicine)

promethazine vc with codeine- promethazine and phenylephrine hydrochloride and codeine phosphate solution

par pharmaceutical - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494), phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - codeine phosphate 10 mg in 5 ml - promethazine vc with codeine oral solution is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold in patients 18 years of age and older. important limitations of use - not indicated for pediatric patients under 18 years of age [see use in specific populations (8.4) ]. - contraindicated in pediatric patients under 12 years of age [see contraindications (4) and use in specific populations (8.4) ]. - contraindicated in pediatric patients 12 to 18 years of age after tonsillectomy or adenoidectomy [see contraindications (4) and use in specific populations (8.4) ]. - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1) ], reserve promethazine vc with codeine oral solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough h